动脉粥样硬化性心血管疾病靶向治疗的临床研究进展

Clinical research progress of targeted therapy for atherosclerotic cardiovascular disease

动脉粥样硬化性心血管疾病(ASCVD)是全球范围首位死亡原因,随着人口老龄化进程,我国心血管病发病率和死亡率持续上升。目前对于ASCVD高危人群的无创筛查和有效治疗仍然存在巨大挑战。在过去的十年中,单克隆抗体和RNA干扰药物等创新疗法进入临床应用,为ASCVD靶向降脂和抗炎治疗提供更为有效的干预手段。同时,针对ASCVD诊疗的仿生药物和纳米制剂相继进入临床研究,取得突破性的进展。本文综述了近年来基于单抗、RNA干扰等创新药物在ASCVD靶向降脂和抗炎治疗方面的临床应用进展,同时总结了基于纳米递送系统的创新药物制剂用于靶向诊疗ASCVD的研究进展。

Atherosclerotic cardiovascular disease(ASCVD)is the leading cause of death worldwide.With the aging of population,the incidence and mortality of cardiovascular disease in China continue to increase.Currently,there are still great challenges in non-invasive screening and effective treatment for ASCVD high-risk population.In the past decade,innovative therapies such as monoclonal antibodies and RNA interference drugs have entered clinical application,providing more effective interventions for ASCVD targeted lipid-lowering and anti-inflammatory treatment.At the same time,biomimetic drugs and nano-agents for ASCVD diagnosis and treatment have successively entered clinical research and made breakthrough progress.This article reviews the clinical application progress of innovative drugs such as monoclonal antibodies and RNA interference in the targeted lipid-lowering and anti-inflammatory treatment of ASCVD in recent years,and summarizes the research progress of innovative drug preparations based on nano-delivery systems for the targeted diagnosis and treatment of ASCVD.